A Study of MDX-1106 in Patients With Selected Refractory or Relapsed Malignancies
Ontology highlight
ABSTRACT: To evaluate the safety, tolerability, efficacy, and pharmacokinetics of MDX-1106 when administered to patients with advanced non-small cell lung cancer, colorectal cancer, malignant melanoma, clear cell renal cell cancer or hormone refractory prostate cancer
DISEASE(S): Adenocarcinoma,Kidney Neoplasms,Carcinoma,Lung Cancer,Melanoma,Colorectal Cancer,Malignant Melanoma,Neoplasms,Prostatic Neoplasms,Carcinoma, Renal Cell,Renal Cancer,Colorectal Neoplasms,Carcinoma, Non-small-cell Lung,Prostate Cancer,Cancer
PROVIDER: 2037574 | ecrin-mdr-crc |
REPOSITORIES: ECRIN MDR
ACCESS DATA